Real-world experience with pembrolizumab toxicities in advanced melanoma patients: a single-center experience in the UK
{{output}}
Aim: We aimed to characterize the safety profile of pembrolizumab in advanced melanoma patients at our center to better reflect 'real-world' data on anti-PD-1 inhibitors. ... ...
